![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » REGENERON COMPLETES ENROLLMENT IN INFLAMMATORY DISEASE TRIAL
REGENERON COMPLETES ENROLLMENT IN INFLAMMATORY DISEASE TRIAL
April 21, 2006
Regeneron Pharmaceuticals has completed enrollment for a pivotal trial in its Phase III program for the treatment of CIAS1-associated periodic syndrome, or CAPS, a spectrum of very rare genetic autoinflammatory disorders.
The trial will include a six-month, placebo-controlled efficacy phase and be followed by a six-month, open label extension phase, which will help to characterize the safety of the IL-1 trap. The efficacy phase of this trial is expected to be completed by the end of 2006.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct